TY - JOUR
T1 - Oral Milrinone in Severe Chronic Heart Failure
AU - Desjardins, S.
AU - Packer, M.
AU - Curfman, G. D.
PY - 1992/6/4
Y1 - 1992/6/4
N2 - To the Editor: Packer et al. (Nov. 21 issue)1 reported that the unfavorable effect of milrinone on the survival of patients with severe congestive heart failure contrasted with the results of previous studies in laboratory animals. The authors suggested that in rats, milrinone does not inhibit phosphodiesterase, increase levels of cyclic AMP (cAMP), or exert positive inotropic effects but, rather, acts as a vasodilator. However, Weishaar et al.,2 cited by Packer et al., did not test milrinone in their study. Although it is well accepted that milrinone is not a positive inotropic agent in rats, the drug has been shown…
AB - To the Editor: Packer et al. (Nov. 21 issue)1 reported that the unfavorable effect of milrinone on the survival of patients with severe congestive heart failure contrasted with the results of previous studies in laboratory animals. The authors suggested that in rats, milrinone does not inhibit phosphodiesterase, increase levels of cyclic AMP (cAMP), or exert positive inotropic effects but, rather, acts as a vasodilator. However, Weishaar et al.,2 cited by Packer et al., did not test milrinone in their study. Although it is well accepted that milrinone is not a positive inotropic agent in rats, the drug has been shown…
UR - http://www.scopus.com/inward/record.url?scp=0026684611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026684611&partnerID=8YFLogxK
U2 - 10.1056/NEJM199206043262311
DO - 10.1056/NEJM199206043262311
M3 - Letter
C2 - 1579141
AN - SCOPUS:0026684611
SN - 0028-4793
VL - 326
SP - 1565
EP - 1567
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 23
ER -